Pavlos Msaouel
Internal Medicine · Houston, TXNPI 1154617983
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (36.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Pfizer accounts for 65.4% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $23,778 and has fallen 97.3% since, to $642 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $386.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$20K
- Exelixis Inc.$7K
- E.r. Squibb & Sons, L.L.C.$3K
- Johnson & Johnson$392
- Novartis$259
- Telix Pharmaceuticals$231
- plus $403 from 5 others
Across 251 payments — averaging $39,575 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$8.1M
- Regeneron$1.1M
- E.r. Squibb & Sons, L.L.C.$400K
- Takeda Pharmaceuticals U.S.A., Inc.$378K
What the payments were for
- Consulting fees$11,21037%
- Speaking & faculty fees$5,46018%
- Travel & lodging$10,90936%
- Food & beverage$2,8379%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 7 | $19,946 |
| Exelixis Inc. | 51 | $6,742 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,539 |
| Johnson & Johnson | 6 | $392 |
| Novartis | 4 | $259 |
| Telix Pharmaceuticals | 2 | $231 |
| Daiichi Sankyo Inc. | 1 | $124 |
| Seagen Inc. | 1 | $113 |
| AstraZeneca | 2 | $98 |
| Regeneron | 1 | $53 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,512 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $5,840 |
| Levothyroxine Sodium | 22 | $181 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.